Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:DMACNASDAQ:INNTNASDAQ:KMPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.21+8.0%$1.92$1.08▼$5.50$9.58M0.9612,553 shs8,776 shsDMACDiaMedica Therapeutics$2.49-4.2%$2.85$1.50▼$4.75$94.52M1.6942,812 shs17,421 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shsN/AKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+1.68%+2.54%-36.65%-53.46%-71.16%DMACDiaMedica Therapeutics-4.23%-1.97%-11.70%-11.70%+44.77%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.92%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADMACDiaMedica Therapeutics0.9673 of 5 stars3.53.00.00.01.40.00.0INNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ADMACDiaMedica Therapeutics3.00Buy$7.00181.12% UpsideINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest INNT, KMPH, DMAC, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AKMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)INNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/ALatest INNT, KMPH, DMAC, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95DMACDiaMedica TherapeuticsN/A19.2719.27INNTInnovate BiopharmaceuticalsN/A0.350.35KMPHZevra Therapeutics0.1410.1010.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%DMACDiaMedica Therapeutics10.12%INNTInnovate Biopharmaceuticals5.88%KMPHZevra Therapeutics19.39%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%DMACDiaMedica Therapeutics7.20%INNTInnovate Biopharmaceuticals7.90%KMPHZevra Therapeutics1.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics157.92 million3.03 millionNot OptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableINNT, KMPH, DMAC, and AKTX HeadlinesSourceHeadlineZevra Therapeutics Shares Fall After FDA Extends Arimoclomol Reviewmarketwatch.com - March 4 at 10:23 AMBrisbane, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 20 at 6:37 PMChristchurch, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 17 at 7:36 PMGreater Bendigo, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - January 11 at 6:36 PMBuy Rating Affirmed for Zevra Therapeutics Amid Positive Regulatory Developments and Strong Market Positioningmarkets.businessinsider.com - January 9 at 11:59 PMZevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type Cmarkets.businessinsider.com - January 8 at 9:34 AMWellington, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - January 6 at 3:29 PMZevra seeks FDA nod for rare disease therapy arimoclomolmsn.com - December 27 at 3:28 PMZevra Therapeutics Refiles Arimoclomol Application With FDAmarketwatch.com - December 27 at 10:28 AMQueenstown, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 23 at 12:45 PMMelbourne, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 11 at 6:42 PMOroquieta City, Philippines - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 11 at 6:42 PMTehran, Iran - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 1 at 7:04 PMZevra Therapeutics: Promising Growth Avenues and Potential Approvals Bolster Buy Ratingmarkets.businessinsider.com - November 9 at 3:27 AMPhnom Penh, Cambodia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - October 26 at 8:36 PMNowra, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - August 26 at 4:01 PMTemuka, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - August 26 at 4:01 PMZevra Therapeutics GAAP EPS of -$0.15 beats by $0.19, revenue of $8.5M beats by $5.47Mseekingalpha.com - August 14 at 4:32 PMManama, Bahrain - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 30 at 3:12 PMKanayannur, India - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 29 at 2:44 AMMonte-Carlo, Monaco - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 29 at 2:44 AMGeneva, Switzerland - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 27 at 9:51 AMBellevue, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 27 at 6:18 AMNairobi, Kenya - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 25 at 11:01 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.